1438P First-line (1L) zolbetuximab + chemotherapy in patients (pts) with claudin 18.2 (CLDN18.2) +, HER2-, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: A pooled final analysis of SPOTLIGHT + GLOW

Authors :: Kang, Y-K.
Shah, M.A.
Shitara, K.
Ajani, J.A.
Lordick, F.
Van Cutsem, E.
Ilson, D.H.
Klempner, S.J.
Yamaguchi, K.
Nakajima, T.
Cao, Y.J.
Li, R.
Moran, D.
Pophale, R.R.
Ranganath, R.
Xu, R-H.
Source :: Annals of Oncology. 2024 Supplement 2, Vol. 35, pS895-S895. 1p.
Publication Year :: 2024

Subjects :: *ESOPHAGOGASTRIC junction
*CLAUDINS
*ADENOCARCINOMA
*CANCER chemotherapy
*METASTASIS

Full Text Access

Tools